Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rang in Aktien #96
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aktienkurs
$43.92
Zuletzt synchronisiert: 2026-09-11
Marktkapitalisierung
$195.10B
Veränderung (1 Tag)
-3.37%
Veränderung (1 Jahr)
-17.97%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)

Kategorie

Kursverlauf für Novo Nordisk A/S (NOVO-B)
Höchster Schlusskurs: $45.23 am 2026-09-01

Niedrigster Schlusskurs: $6.85 am 2010-02-01
Kursverlauf der Aktie von Novo Nordisk A/S von 2010 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -3.05%
2025 -51.49%
2024 1.66%
2023 53.39%
2022 17.33%
2021 57.90%
2020 22.88%
2019 26.30%
2018 -13.92%
2017 49.76%
2016 -37.96%
2015 26.26%
2014 24.70%
2013 10.83%
2012 43.56%
2011 6.06%
2010 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$1.11K 47.49%
US
$265.87 49.31%
US
$257.01 17.71%
US
$459.10 30.72%
CH
$144.05 73.95%
US